ERBB2 and ductal breast carcinoma in situ: By analysis of 28 DCIS patient samples, we demonstrated that DCIS lesions expressing higher nuclear BCL9 (percentage of cells expressing nuclear BCL9) were more likely to be ER-negative, PR-negative, high nuclear grade, and high in HER2 expression.